{
    "info": {
        "nct_id": "NCT05512390",
        "official_title": "A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies",
        "inclusion_criteria": "* For dose escalation (Part 1) only: Participants with documented diagnosis of B-cell malignancies including those with histology based on criteria established by the World Health Organization (WHO), and measurable disease requiring treatment, as per the protocol.\n* For the relapsed or refractory diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and Chronic lymphocytic leukemia (CLL) dose expansion cohorts (Part 2) only: Participants with documented diagnosis of one of the B-cell malignancies noted in the protocol with histology based on criteria established by the WHO, and measurable disease requiring treatment, as per the protocol.\n* Laboratory values meeting the criteria noted in the protocol.\n* For participants previously treated with a CD19-targeting therapy (eg, CD19 monoclonal antibody) a core or excision tumor biopsy subsequent to the most recent CD19-targeting therapy must be collected.\n* Participant must have measurable disease, as defined by the 2014 Lugano Classification.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Known active central nervous system (CNS) disease, or primary CNS lymphoma.\n* Known active infection or clinically significant uncontrolled conditions as per the protocol.\n* Eastern Cooperative Oncology Group (ECOG) performance status >= 2.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* For participants previously treated with a CD19-targeting therapy (eg, CD19 monoclonal antibody) a core or excision tumor biopsy subsequent to the most recent CD19-targeting therapy must be collected.",
            "criterions": [
                {
                    "exact_snippets": "participants previously treated with a CD19-targeting therapy",
                    "criterion": "prior CD19-targeting therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "a core or excision tumor biopsy subsequent to the most recent CD19-targeting therapy must be collected",
                    "criterion": "tumor biopsy collection after most recent CD19-targeting therapy",
                    "requirements": [
                        {
                            "requirement_type": "collection",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "after most recent CD19-targeting therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For the relapsed or refractory diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and Chronic lymphocytic leukemia (CLL) dose expansion cohorts (Part 2) only: Participants with documented diagnosis of one of the B-cell malignancies noted in the protocol with histology based on criteria established by the WHO, and measurable disease requiring treatment, as per the protocol.",
            "criterions": [
                {
                    "exact_snippets": "documented diagnosis of one of the B-cell malignancies noted in the protocol",
                    "criterion": "B-cell malignancy diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "histology based on criteria established by the WHO",
                    "criterion": "histology",
                    "requirements": [
                        {
                            "requirement_type": "criteria source",
                            "expected_value": "WHO"
                        }
                    ]
                },
                {
                    "exact_snippets": "measurable disease requiring treatment",
                    "criterion": "measurable disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "requires treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must have measurable disease, as defined by the 2014 Lugano Classification.",
            "criterions": [
                {
                    "exact_snippets": "Participant must have measurable disease, as defined by the 2014 Lugano Classification.",
                    "criterion": "measurable disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "definition standard",
                            "expected_value": "2014 Lugano Classification"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For dose escalation (Part 1) only: Participants with documented diagnosis of B-cell malignancies including those with histology based on criteria established by the World Health Organization (WHO), and measurable disease requiring treatment, as per the protocol.",
            "criterions": [
                {
                    "exact_snippets": "Participants with documented diagnosis of B-cell malignancies",
                    "criterion": "B-cell malignancy diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "histology based on criteria established by the World Health Organization (WHO)",
                    "criterion": "histology",
                    "requirements": [
                        {
                            "requirement_type": "criteria",
                            "expected_value": "established by the World Health Organization (WHO)"
                        }
                    ]
                },
                {
                    "exact_snippets": "measurable disease requiring treatment",
                    "criterion": "measurable disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Laboratory values meeting the criteria noted in the protocol.",
            "criterions": [
                {
                    "exact_snippets": "Laboratory values meeting the criteria noted in the protocol",
                    "criterion": "laboratory values",
                    "requirements": [
                        {
                            "requirement_type": "meets protocol criteria",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Known active infection or clinically significant uncontrolled conditions as per the protocol.",
            "criterions": [
                {
                    "exact_snippets": "Known active infection",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant uncontrolled conditions",
                    "criterion": "clinically significant uncontrolled conditions",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status >= 2.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status >= 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": ""
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known active central nervous system (CNS) disease, or primary CNS lymphoma.",
            "criterions": [
                {
                    "exact_snippets": "Known active central nervous system (CNS) disease",
                    "criterion": "central nervous system (CNS) disease",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "awareness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "primary CNS lymphoma",
                    "criterion": "primary CNS lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}